Canada· CA-DIN-02551918

MAR-LEFLUNOMIDE

A leflunomide product containing leflunomide, registered in Canada by MARCAN PHARMACEUTICALS INC. The same ATC class is registered in 15 of our 19 countries.

ATC L04AK01

Checked against Health Canada Drug Product Database (Canada) on

Informational only — not a medical device.

SOURCE REGISTER · CAHealth Canada Drug Product Database (Ca…normalisedMAR-LEFLUNOMIDEATCL04AK01REGISTER NO.CA-DIN-02551918PACKS LISTED0CHECKEDOctober 1, 2026

Where it is registered

Leflunomide is registered in 15 of 19 countries.

Countries holding a registration under ATC L04AK01 (leflunomide), each read from that country’s own register.

  • This record: Canada, from Health Canada Drug Product Database (Canada)
  • 9 of them publish a price we can compare per daily dose

Leflunomide · ATC L04AK01

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Germany
  • Icelandprice
  • Italyprice
  • Japan
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of leflunomide costs, country by country.

Normalised to the WHO defined daily dose (20 mg), the median price runs from $0.47 in United States to $2.13 in Italy — a ×4.5 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown
  • US figures are pharmacy acquisition cost (CMS NADAC), not retail

Leflunomide · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • IT Italy$2.13
  • CH Switzerland$1.48
  • US United States$0.47 (acquisition cost)
Median listed price per WHO defined daily dose, in each market that publishes a price. US = pharmacy acquisition cost (CMS NADAC), not a retail price. Open the full comparison

The record

At a glance

Health Canada Drug Product Database (Canada)
Active substance
LEFLUNOMIDE
Manufacturer
MARCAN PHARMACEUTICALS INC
Country
Canada (CA)
ATC code
L04AK01
ATC class
Leflunomide
Defined daily dose
20 mg, O
Reimbursed
Not published by this register
Source register
Health Canada Drug Product Database (Canada)
Last checked
October 1, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

805 interactions on record for leflunomide.

Graded by severity as the source publishes them — 537 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Leflunomide · interactions on record

805 records

  • 537 severe
  • 47 moderate
  • 7 minor
  • 214 info

Most severe, free to view

  • ClotrimazoleA01AB18severe
  • Chenodeoxycholic acidA05AA01severe
  • PrednisoloneA07EA01severe
  • HydrocortisoneA07EA02severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Leflunomide in 16 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All leflunomide products

Authorised across Europe · EMA

The same active substance is authorised in 27 EEA countries. Names it is sold under:

  • Austria · Leflunomid Stada
  • Belgium · Leflunomid Sandoz, Leflunomide Ab
  • Bulgaria · Багеда
  • Cyprus · Arotan
  • Czechia · Leflon, Leflugen
  • Germany · Leflon, Leflunomid 1 A Pharma
  • Denmark · Leflunomid, Leflunomid "egis"
  • Estonia · Leflunomide Elvim
  • Spain · Lefluartil, Leflunomida Aurovitas
  • Finland · Leflunomide Orion, Leflunomide Stada
  • France · Leflunomide Arrow, Leflunomide Biogaran
  • United Kingdom (Northern Ireland) · Leflunomide Aspire Pharma, Leflunomide Milpharm
  • Greece · Lefid, Lefluonia
  • Hungary · Leflunomid Sandoz
  • Ireland · Leflunomide Aspire Pharma (Malta)
  • Iceland · Arava, Leflunomide Medac
  • Italy · Leflunomide Aurobindo, Leflunomide Mylan
  • Liechtenstein · Arava, Leflunomide Medac
  • Lithuania · Leflunomide Elvim, Leflunomide Sandoz
  • Latvia · Leflunomide Elvim, Leflunomide Sandoz
  • Malta · Leflunomide Normon
  • Netherlands · Leflunomide Aurobindo, Leflunomide Cf
  • Norway · Arava, Leflunomide Medac
  • Poland · Leflunomid Bluefish, Leflunomid Egis
  • Portugal · Leflunomida Farmoz, Leflunomida Generis
  • Romania · Leflon, Leflunomidă Arena
  • Sweden · Leflunomid Bluefish

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Health Canada Drug Product Database (Canada). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/ca3503f3-882e-4bde-bf85-6486e8fd6b11
GET /v1/drugs/ca3503f3-882e-4bde-bf85-6486e8fd6b11?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "din": "02551918",
  "form": "TABLET",
  "class": "Human",
  "routes": [
    "ORAL"
  ],
  "source": "health_canada_dpd",
  "status": "MARKETED",
  "atc_raw": "L04AK01",
  "schedule": [
    "Prescription"
  ],
  "drug_code": "104061",
  "strengths": [
    "10 MG"
  ],
  "ahfs_class": null,
  "substances": [
    "LEFLUNOMIDE"
  ],
  "product_categorization": null
}

See everything about leflunomide.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.